David F. Hale has joined the board of Biocept Inc. as executive chairman and Ivor Royston, M.D. as a director.
The two first worked together at Hybritech, San Diego's first biotech company, of which Royston was a co-founder and director, and Hale, president and COO and as CEO when the company was acquired by Eli Lilly & Co.They also worked together at the oncology company, CancerVax Inc., which was merged with Micromet, Inc. in 2006.
Biocept is a San Diego-based diagnostic and laboratory services company focused on the capture, detection, enumeration and analysis of circulating tumor cells (CTCs) to provide information to physicians to enhance the treatment of patients with cancer. The company is planning to launch its first product, OncoCEE-BR™ for breast cancer, in the third quarter of this year.
Since 2006 Hale has been Chairman and CEO of Hale BioPharma Ventures, LLC a private venture company that has been involved in the founding, formation and/or development of over 10 biotechnology, specialty pharma, diagnostic and medical device companies.
Since 1990, Dr. Royston is a founding Managing Partner of Forward Ventures in San Diego, from 1990-2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was on the oncology faculty of UCSD.